Press Release

G2GBio has the best subject matter experts in the field of the injectable drug development.

[Interview] G2GBIO Expands Beyond Long-Acting Drug Delivery Technology into Antibody SC Formulations, Secures New Growth Engine
2026.08.07
HIT 1654

[Interview] G2GBIO Expands Beyond Long-Acting Drug Delivery Technology into Antibody SC Formulations, Secures New Growth Engine



- Achieves up to 750 mg/mL in IgG experiments with confirmed 27G needle penetration
- “Existing microsphere processes eliminate the need for separate production infrastructure”
- “Celltrion collaboration expected to catalyze expansion of antibody subcutaneous formulation business”
- CEO Lee Hee-yong introduces ‘InnoBioLAMP,’ an ultra-high concentration antibody subcutaneous delivery platform
- Broad antibody applicability under verification as company pursues global joint research and licensing agreements


[by Ji, Yong Jun] “G2GBIO has focused on improving patient convenience through its microparticle-based long-acting injectable platform. We now aim to establish a new growth engine by expanding into antibody therapeutics.”

In a written interview with on July 31, G2GBIO CEO Lee Hee-yong revealed plans to develop ultra-high concentration subcutaneous (SC) antibody formulations as a new business area. The strategy involves applying the company’s existing microparticle manufacturing technology to antibody drugs, with the aim of expanding opportunities for joint research and technology transfer with global pharmaceutical companies.

“Microparticle-based long-acting injectables can enhance patient treatment convenience and treatment adherence by reducing dosing frequency. Antibody SC formulations can simplify treatments that previously required prolonged administration in hospitals,” Lee remarked.

◇Addressing the limitations of high-concentration liquids…‘InnoBioLAMP’ unveiled

On the previous day (July 30), G2GBIO unveiled ‘InnoBioLAMP,’ an ultra-high concentration antibody SC formulation platform. Converting antibody therapeutics into subcutaneous (SC) formulations requires high-concentration technology capable of delivering the necessary dose within a limited volume of 1–2 mL. However, higher antibody concentrations can increase viscosity and compromise biophysical stability. InnoBioLAMP was developed to overcome these limitations of high-concentration liquid formulations by converting antibodies into microparticles and suspending them in a non-aqueous carrier.

Using InnoBioLAMP, G2GBIO confirmed the feasibility of producing microparticle from 'semaglutide' (molecular weight of approximately 4.1 kilodaltons (kDa), 'bovine serum albumin (BSA)' (66.5 kDa), and 'bevacizumab' (149 kDa). According to G2GBIO, microparticles produced from all three substances maintained a uniform, densely packed spherical structure despite their differing molecular weights. Based on these findings, the company plans to expand InnoBioLAMP into a high-concentration formulation platform applicable to a broad range of biopharmaceuticals.

In fact, G2GBIO has achieved an antibody microparticle suspension formulation with a maximum concentration of 750 mg/mL using immunoglobulin G (IgG). The company explained that this performance surpasses that of global competitors developing subcutaneous (SC) formulations, as Elektrofi’s ‘Hypercon’ supports concentrations of up to 500 mg/mL, while Lindy Biosciences’ ‘Microglassification’ is limited to 400 mg/mL.
In particular, Lee noted that, in G2GBIO’s internal testing, the 750 mg/mL SC formulation required an injection of approximately 14 Newtons (N) when administered through a 27-gauge (G) needle. This falls within the threshold of 20 N or less, allowing high-concentration drugs to be gently injected through a thin needle, either manually or with a device.

Lee highlighted InnoBioLAMP’s compatibility with the company’s existing long-acting peptide microsphere manufacturing processes as a key advantage for production scalability. This would allow the company to minimize the need for separate manufacturing infrastructure and mitigate scale-up risks, facilitating the platform’s integration into Good Manufacturing Practice (GMP) processes.

◇PoC secured through joint research, with technology transfer to global pharmaceutical companies in pursuit

G2GBIO plans to establish proof of concept (PoC) by evaluating the applicability of InnoBioLAMP across a range of antibodies. The company is also seeking co-development opportunities, technology transfer agreements, and strategic partnerships with major global pharmaceutical companies.

In particular, the business agreement signed with Celltrion on July 30 is expected to provide an opportunity to expand G2GBIO’s antibody SC formulation business. Once the collaboration takes shape, G2GBIO expects to explore the platform’s potential application not only to antibody therapeutics but also drug candidates targeting obesity and metabolic diseases.

Lee plans to focus on translating technological development into tangible business outcomes. "What G2GBIO is developing is more than a simple formulation, it is a technology that gives patients back their time. I believe true innovation lies in improving not only therapeutic efficacy but also the treatment process," Lee said.

"We will intensify our efforts to ensure that the technological capabilities G2GBIO has built translate into tangible business results and revenue. We aim to provide patients with more valuable treatment experiences and grow into a platform company recognized in the global biopharmaceutical market," he further emphasized.